12:00 AM
 | 
Jan 26, 2015
 |  BC Week In Review  |  Company News  |  Deals

Sellas, Catalent Pharma deal

Catalent and Sellas partnered to reprofile insomnia drug zolpidem to treat Parkinson’s disease (PD) and progressive supranuclear palsy...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >